Cargando…

1343. Prophylactic Dosing of Baloxavir Acid Eliminates Mortality in Mice Lethal Influenza A Virus Infection Model

BACKGROUND: Baloxavir acid (BXA), an active form of orally available prodrug baloxavir marboxil (BXM, formerly S-033188), is a novel small molecule inhibitor of cap-dependent endonuclease (CEN) of influenza A and B virus, and was recently launched for the treatment of acute and uncomplicated influen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shano, Shinya, Fukao, Keita, Noshi, Takeshi, Sato, Kenji, Sakuramoto, Masashi, Baba, Kaoru, Shishido, Takao, Naito, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253271/ http://dx.doi.org/10.1093/ofid/ofy210.1174

Ejemplares similares

Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses
por: Fukao, Keita, et al.
Publicado: (2023)

Carryover effects of baloxavir acid in human nasopharyngeal/pharyngeal swabs on infectious titer testing of influenza virus
por: Baba, Keiko, et al.
Publicado: (2020)

In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses
por: Kuroda, Takayuki, et al.
Publicado: (2023)

Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection
por: Fukao, Keita, et al.
Publicado: (2019)

Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models
por: Fukao, Keita, et al.
Publicado: (2019)

Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil
por: Omoto, Shinya, et al.
Publicado: (2018)

Delayed Dosing of S-033188, a Novel Inhibitor of Influenza Virus Cap-dependent Endonuclease, Exhibited Significant Reduction of Viral Titer and Mortality in Mice Infected with Influenza A Virus
por: Fukao, Keita, et al.
Publicado: (2017)

1350. Therapeutic Effects of Baloxavir Marboxil against Influenza A Virus Infection in Ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2018)

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
por: Taniguchi, Keiichi, et al.
Publicado: (2022)

The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets
por: Kitano, Mitsutaka, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection
por: Ando, Yoshinori, et al.
Publicado: (2020)

Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil
por: Taniguchi, Keiichi, et al.
Publicado: (2019)

Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes
por: Hirotsu, Nobuo, et al.
Publicado: (2020)

Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil
por: Hashimoto, Takashi, et al.
Publicado: (2020)

Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial
por: Portsmouth, Simon, et al.
Publicado: (2020)

Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study
por: Yokoyama, Takato, et al.
Publicado: (2020)

Synergistic Antiviral Activity of S-033188/S-033447, a Novel Inhibitor of Influenza Virus Cap-Dependent Endonuclease, in Combination with Neuraminidase Inhibitors In Vitro
por: Kitano, Mitsutaka, et al.
Publicado: (2017)

LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study)
por: Ison, Michael G, et al.
Publicado: (2018)

Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission
por: Lee, Leo Yi Yang, et al.
Publicado: (2020)

Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan
por: Hirotsu, Nobuo, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model
por: Fukao, Keita, et al.
Publicado: (2023)

Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model
por: Lee, Leo Y, et al.
Publicado: (2021)

Roles of B739_1343 in iron acquisition and pathogenesis in Riemerella anatipestifer CH-1 and evaluation of the RA-CH-1ΔB739_1343 mutant as an attenuated vaccine
por: Liu, MaFeng, et al.
Publicado: (2018)

Metabolic or Ischemic Stroke in Succinic Semi-aldehyde Dehydrogenase Deficiency Due to the Homozygous Variant c. 1343 + 1_1343 + 3delGTAinsTT in ALDH5A1
por: Finsterer, Josef, et al.
Publicado: (2021)

Metabolic Or Ischemic Stroke in Succinic Semi-Aldehyde Dehydrogenase Deficiency Due to the Homozygous Variant c. 1343 + 1_1343 + 3delGTAinsTT in ALDH5A1
por: Yoganathan, Sangeetha, et al.
Publicado: (2021)

Modeling mitigation of influenza epidemics by baloxavir
por: Du, Zhanwei, et al.
Publicado: (2020)

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
por: Twabela, Augustin, et al.
Publicado: (2020)

P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022)

P1343: TNIK SIGNALLING IMPAIRS SELF-RENEWAL AND LONG-TERM RECONSTITUTION CAPACITY OF HSCS
por: Palombella, Luca, et al.
Publicado: (2023)

The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice
por: Yoshii, Naoko, et al.
Publicado: (2020)

Efficacy of baloxavir marboxil on household transmission of influenza infection
por: Umemura, Takumi, et al.
Publicado: (2020)

Baloxavir Marboxil: An Original New Drug against Influenza
por: Dufrasne, François
Publicado: (2021)

1645. Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of Otherwise Healthy Adults/Adolescents in Seasonal Influenza: Impact on Regional Participants, Treatment Time and Influenza Type B Virus Infection (CAPSTONE-1 Study)
por: Kawaguchi, Keiko, et al.
Publicado: (2018)

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
por: Mishin, Vasiliy P., et al.
Publicado: (2019)

1343. Clinical Outcome of Penicillin Skin Testing as an Antimicrobial Stewardship Initiative in the pre-surgical clinic in a community hospital
por: rahbani, peggy, et al.
Publicado: (2020)

Reduced Prescription of Baloxavir After Suspected Prevalence of a Baloxavir-Resistant Influenza Virus Strain and the Emergence of SARS-CoV-2 in a Tertiary Hospital in Japan
por: Kamioka, Yasuhiro, et al.
Publicado: (2020)

Prophylactic efficacy of some chemoprotectants against abrin induced lethality
por: Saxena, Nandita, et al.
Publicado: (2018)

Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil
por: Takashita, Emi, et al.
Publicado: (2018)

97. Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant
por: Checkmahomed, Liva, et al.
Publicado: (2019)

2645. Clinical Outcomes of Oseltamivir vs. Baloxavir in Patients Hospitalized with Influenza A
por: Shah, Sunish, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4d3i2m4m52od5p8usvrpludedd